TL;DR
- •Musicians and performing artists have substantially elevated suicide rates compared to the general population — recent reviews (Musgrave 2025) document the music-industry suicide and depression burden, with similar elevated prevalence across actors and touring crew.
- •Rejection cycles, income volatility, tour exhaustion, public scrutiny, identity-tied-to-art, and an industry culture that normalizes substance use create a stressor profile that's distinct from any salaried profession.
- •Telehealth ketamine therapy fits the touring or production schedule — sessions during off weeks or at home base, no clinic visits where industry people might see you, completely private from agents, managers, and publicists.
- •Tovani is direct-pay ($349/month, HSA/FSA eligible) — bypasses union health plans (SAG-AFTRA, AFM, IATSE) and producer-paid insurance, keeping treatment outside any production-side record.
- •For treatment-resistant cases where SSRIs, therapy, and the industry's standard "go to rehab" approach haven't produced enough response, ketamine's rapid mechanism is meaningful — particularly when tour or production timelines don't allow 6-12 weeks of SSRI titration.
- •Most entertainment-patients say what mattered most was: a non-judgmental clinical environment about substance-use exposure; ability to schedule around tour dates and shoot schedules; same physician every visit; complete separation from any union or production-side health record.
The stressors specific to your work
- •Rejection cycles — auditions, pitches, A&R meetings where the no-rate dwarfs the yes-rate
- •Income volatility — feast-or-famine pay structure with multi-year gaps between projects
- •Tour exhaustion or production-schedule depletion — sustained 12-16 hour days with no real recovery window
- •Public scrutiny — social media, press, fan culture creating sustained external evaluation
- •Identity-tied-to-art — career setbacks landing as personal-worth crises
- •Industry-normalized substance use creating environments that suppress sobriety and confuse mental-health symptoms with intoxication patterns
Why telehealth works for entertainment industry
- •Sessions during off weeks, hiatus, or at home base between tour legs
- •No commute — fits around shoot schedules, sound checks, and writing sessions
- •Treatment in your own home — completely private from agents, managers, publicists, and industry colleagues
- •Same physician every visit — continuity in an industry built on rotating teams
- •Completely separate from union health plans or producer-paid insurance trails
Privacy considerations
- •Tovani is direct-pay — no insurance claim tied to union health plan (SAG-AFTRA, AFM, IATSE, DGA, WGA) or producer-paid coverage.
- •Patient records are private and NEVER visible to agents, managers, publicists, labels, studios, networks, or any industry party without your explicit written authorization.
- •For artists with public personas, the privacy considerations are amplified — Tovani's telehealth-only model means no clinic foot traffic, no waiting-room recognition, and no medical-office records discoverable via standard background investigations.
- •Insurance and union health records, when used, do appear in claim trails that some union members prefer to avoid — direct-pay bypasses this entirely.
5-minute screening · Reviewed by a board-certified physician · FL & NJ · $349/month
Frequently asked
I'm touring — can I do this on the road?
Tovani serves FL and NJ residents specifically; sessions require you to be physically in one of those states during the dosing window. For touring artists with a residency in FL or NJ, sessions are scheduled during home base or off weeks. We do not offer in-tour treatment in other states (that would violate licensure laws). Many artist-patients plan the initial treatment phase around a tour break.
I drink and use cannabis routinely — will Tovani still treat me?
Yes — and we won't lecture you. Substance use in entertainment is structural to the industry, not personal failure. The honest conversation with your physician is about what's safe and effective given that pattern. Sometimes substance moderation needs to come first; sometimes treatment can proceed alongside ongoing use with specific protocols. The AUDIT-C and other screening tools on this site can help frame that conversation.
My agent and label monitor my insurance claims for production-bond purposes. Will they see this?
Production-bond medical reviews look at conditions affecting your ability to complete a production. Tovani is direct-pay — there's no insurance claim filed unless you submit one yourself for reimbursement, and even then the claim only includes line items, not clinical detail. Patient records are HIPAA-protected and not subject to standard production-bond medical reviews unless you specifically authorize disclosure. Most artist-patients keep this entirely separate from their professional-side medical records.
I've been to rehab twice. Is ketamine right or risky?
This is a clinical conversation with your physician based on what you used, your sobriety history, and the specific reasons rehab didn't produce lasting change. Ketamine in dissociative-anesthetic doses has a different misuse risk profile than alcohol or opioids; in controlled outpatient settings with proper screening, the misuse risk is low. For some patients with substance-use history, ketamine is appropriate; for others, prioritizing stable sobriety first is the right sequence. Your physician helps decide.
I've been depressed for years and SSRIs make me feel flat creatively. What now?
A common pattern in creative professions. Options: switching to Wellbutrin (NDRI, less likely to cause creative flatness than SSRIs), mechanism-switching to ketamine, or augmentation. Many artist-patients specifically choose ketamine because the NMDA/glutamate mechanism doesn't produce the chronic serotonergic effects that some patients describe as "creative flatness." Reports of improved creative output during ketamine treatment are common.
References
- Musgrave G, Lamis DA 2025, Suicide and Life-Threatening Behavior. Review of musician suicide epidemiology and industry-specific risk factors — establishes the case for industry-tailored treatment pathways that account for substance-use prevalence and tour-schedule constraints. PMID 40124411
- Murrough JW et al. 2013, American Journal of Psychiatry. Ketamine RCT showed 64% response in treatment-resistant depression — relevant for high-prevalence creative industries where prior SSRI trials and "go to rehab" approaches have often produced partial response. PMID 23982301
- Sanacora G et al. 2017, JAMA Psychiatry. APA consensus on ketamine's rapid antidepressant effects — particularly relevant when production or tour timelines don't allow waiting weeks for SSRIs to titrate. PMID 28249076